EAM
ONC

Exome Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Exome Asset Management’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Buy
+10,000
New +$3.24M 1.54% 26

Other funds holding ONC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Exome Asset Management's ONC Position: Q2 2025 in Review

Exome Asset Management sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 6,500 shares — an estimated $1.77M sold.

Exome Asset Management first reported a position in ONC in Q4 2023 and held it in 6 quarters. The position peaked at $5.76M in Q1 2024. 243 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

  • Exome Asset Management reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
  • Exome Asset Management sold 6,500 BeOne Medicines Ltd shares in Q2 2025, an estimated $1.77M.
  • Exome Asset Management first reported a position in BeOne Medicines Ltd in Q4 2023 and held it in 6 quarters.
  • Exome Asset Management's BeOne Medicines Ltd position peaked at $5.76M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.